ENSC

Ensysce Biosciences, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001716947 Biotech & Drug Discovery

$0.4710 −0.04 (−7.83%)

Oct 23 4:00 PM ET · prev $0.5110

Market cap

$9.9M

Nano cap

Consensus

Buy

86% Buy or better · 7 analysts

Median target

🔒 Subscribers only

1 year

−78.9%

from $2.23 · Oct 24

30 days

+17.7%

from $0.4000

52-week range

$0.2510–2.23

−79% from high · low Jun 12

Avg volume 20D

578.1K

Oct 9 spike 2.68M

Short interest

1.08M

≈5.6% of shares · −10.4%

Days to cover

3.4

at average volume

Insider net

+$444.2K

1 buyer · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 2 reports · 90 days

Balance 2 bearish · 0 bullish oldest → newest, height = score

Avg score

·High conf. 2/2 ·Next Earnings date, Nov 12, 2026

Strongest BEARISH Ensysce Biosciences filed an S-3 registration statement to register up to 433,907,000 shares of common stock…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Apr 23 1 insider buy $246.2K at $0.4840
E Aug 6 Trading halt: Halt Resumed: ENSC — trading resumed after LUDP (Volatilit…
B Aug 7 1 insider buy $198.0K at $0.4950
X Aug 14 Short interest jumps 496.0% to 1.14M
R Aug 25 Ensysce Biosciences filed an 8-K disclosing three Nasdaq compliance…
X Aug 31 Short interest jumps 25.1% to 1.43M
A Oct 20 Cantor Fitzgerald initiates
R Oct 23 Ensysce Biosciences filed an S-3 registration statement to register…

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $444.2K at an average $0.4888. No open-market sales.
InstitutionsMIXED

Q2 2026: 2 added (0 new), 0 trimmed or exited.
AnalystsBULLISH

6 of 7 rate it Buy or better.
Short sellersSTEADY

Short interest −10.4% to 1.08M shares. 3.4 days to cover, ≈5.6% of shares.
TrendUPTREND

6% above its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
JANE STREET GROUP, LLC	DOUBLED	208,833	$60.6K
CITADEL ADVISORS LLC	ADD	86,193	$25.0K
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	73,880	$39.8K
UBS Group AG	DOUBLED	8,791	$4.7K
ADAGE CAPITAL PARTNERS GP, L.L.C.	DOUBLED	149,711	$137.7K
GEODE CAPITAL MANAGEMENT, LLC	ADD	22,090	$20.3K
UBS Group AG	NEAR_EXIT	100	$92.00
BANK OF AMERICA CORP /DE/	DOUBLED	72	$66.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts

Buy 86% rate it Buy or better

Strong Buy2Buy4Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Oct 20, 2026	Cantor Fitzgerald INITIATE	INITIATE	Overweight

Insider ledger

Form 4

$444.2K

bought · 1 insider

sold · 0 insiders

−3.6%

vs their $0.4888 cost

Date	Insider	Type	Value
Aug 7, 2026	GOWER BOB G Director	BUY	$198.0K
Apr 23, 2026	GOWER BOB G Director	CONVERT	254,307 sh
Apr 23, 2026	GOWER BOB G Director	BUY	$246.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data — subscribers only
Next Q	🔒 Fresh data — subscribers only
Current FY	🔒 Fresh data — subscribers only
Next FY	🔒 Fresh data — subscribers only